FI2827862T3 - Bendamustiinin formulaatioita - Google Patents

Bendamustiinin formulaatioita Download PDF

Info

Publication number
FI2827862T3
FI2827862T3 FIEP13764989.3T FI13764989T FI2827862T3 FI 2827862 T3 FI2827862 T3 FI 2827862T3 FI 13764989 T FI13764989 T FI 13764989T FI 2827862 T3 FI2827862 T3 FI 2827862T3
Authority
FI
Finland
Prior art keywords
liquid composition
polyethylene glycol
propylene glycol
bendamustine
subject
Prior art date
Application number
FIEP13764989.3T
Other languages
English (en)
Finnish (fi)
Inventor
Srikanth Sundaram
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI2827862(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Application granted granted Critical
Publication of FI2827862T3 publication Critical patent/FI2827862T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FIEP13764989.3T 2012-03-20 2013-03-15 Bendamustiinin formulaatioita FI2827862T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613173P 2012-03-20 2012-03-20
US201261669889P 2012-07-10 2012-07-10
PCT/US2013/032289 WO2013142358A1 (en) 2012-03-20 2013-03-15 Formulations of bendamustine

Publications (1)

Publication Number Publication Date
FI2827862T3 true FI2827862T3 (fi) 2024-02-13

Family

ID=49212372

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP13764989.3T FI2827862T3 (fi) 2012-03-20 2013-03-15 Bendamustiinin formulaatioita

Country Status (15)

Country Link
US (19) US9034908B2 (enExample)
EP (2) EP4360621A3 (enExample)
JP (8) JP6250628B2 (enExample)
CN (1) CN104302291A (enExample)
CA (1) CA2867295C (enExample)
DK (1) DK2827862T3 (enExample)
ES (1) ES2972227T3 (enExample)
FI (1) FI2827862T3 (enExample)
HR (1) HRP20240056T1 (enExample)
HU (1) HUE064884T2 (enExample)
PL (1) PL2827862T3 (enExample)
PT (1) PT2827862T (enExample)
RS (1) RS65177B1 (enExample)
SI (1) SI2827862T1 (enExample)
WO (1) WO2013142358A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054836T2 (hu) * 2010-01-28 2021-10-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelései
JP6224064B2 (ja) 2012-03-20 2017-11-01 イーグル・ファーマシューティカルズ・インコーポレーテッド 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
HRP20240056T1 (hr) * 2012-03-20 2024-03-29 Eagle Pharmaceuticals, Inc. Formulacije bendamustina
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
CN109953954A (zh) 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
CN110772480B (zh) * 2016-03-25 2022-05-17 南京百劲企业管理咨询有限公司 苯达莫司汀药剂组合物及应用
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
CA3108321A1 (en) 2018-08-17 2020-02-20 Hospira Australia Pty Ltd Liquid bendamustine pharmaceutical compositions
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
CA3054834C (en) * 2019-05-20 2025-06-17 MAIA Pharmaceuticals, Inc. READY-TO-USE BIVALIRUDINE COMPOSITIONS
US11992514B2 (en) 2019-05-20 2024-05-28 MAIA Pharmaceuticals, Inc. Ready-to-use bivalirudin compositions
EP4134068A4 (en) * 2020-04-09 2024-02-07 Bika Biotechnology (Guangzhou) Co., Ltd. Bendamustine composition and use thereof
US11707450B1 (en) 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159289C (enExample) 1903-10-08 1905-03-16
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de) 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
NZ279443A (en) 1994-01-24 1998-04-27 Procter & Gamble Solubilizing difficultly soluble pharmaceutical agents using a mixture of polyethylene glycol, polyvinylpyrrolidone and propylene glycol
CA2294247C (en) 1997-07-01 2004-10-26 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
EP1004305B1 (en) 1998-04-20 2011-09-28 Eisai R&D Management Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
ES2300622T3 (es) 2002-07-30 2008-06-16 Wyeth Formulaciones parenterales que contienen un hidroxiester de rapamicina.
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
CA2585659A1 (en) 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
ES2350452T3 (es) 2004-11-22 2011-01-24 Venus Remedies Limited Formulación parenteral de aceclofenaco líquido no acuoso.
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
ES2365410T3 (es) 2005-04-08 2011-10-04 Amylin Pharmaceuticals, Inc. Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico.
JPWO2008020584A1 (ja) 2006-08-14 2010-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定な凍結乾燥製剤
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8414909B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
DE102007003184A1 (de) 2007-01-22 2008-07-24 Orlowski, Michael, Dr. Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en) 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (en) 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
US8076366B2 (en) 2009-01-15 2011-12-13 Cephalon, Inc. Forms of bendamustine free base
CA2753641C (en) 2009-02-25 2014-09-16 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
EP2424506A1 (en) * 2009-04-28 2012-03-07 Cephalon, Inc. Oral formulations of bendamustine
CN101584668A (zh) 2009-06-19 2009-11-25 江苏奥赛康药业有限公司 盐酸苯达莫司汀冻干粉针剂
WO2010148288A2 (en) 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US20110015245A1 (en) 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US8389558B2 (en) 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
HUE054836T2 (hu) * 2010-01-28 2021-10-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelései
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013540104A (ja) 2010-07-28 2013-10-31 イーグル・ファーマシューティカルズ・インコーポレーテッド 延長された保存安定性を有するペメトレキセドを含有する医薬組成物
AU2012347972B2 (en) 2011-12-05 2018-05-10 X-Body, Inc. PDGF receptor beta binding polypeptides
US20130210878A1 (en) * 2012-01-24 2013-08-15 Innopharma, Inc. Bendamustine compositions and methods therefore
KR101951319B1 (ko) * 2012-02-07 2019-02-22 삼성전자주식회사 가변 초점 렌즈
JP2015506989A (ja) * 2012-02-14 2015-03-05 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチン製剤
JP6224064B2 (ja) * 2012-03-20 2017-11-01 イーグル・ファーマシューティカルズ・インコーポレーテッド 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
HRP20240056T1 (hr) * 2012-03-20 2024-03-29 Eagle Pharmaceuticals, Inc. Formulacije bendamustina
US9587397B1 (en) * 2015-09-29 2017-03-07 John Milner McCary, SR. Insulating and support assembly
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion

Also Published As

Publication number Publication date
US20180369383A1 (en) 2018-12-27
US20160144034A1 (en) 2016-05-26
US20190192659A1 (en) 2019-06-27
RS65177B1 (sr) 2024-03-29
EP4360621A2 (en) 2024-05-01
JP2019214592A (ja) 2019-12-19
JP6570601B2 (ja) 2019-09-04
JP2022130630A (ja) 2022-09-06
US20180185488A1 (en) 2018-07-05
JP7133070B2 (ja) 2022-09-07
ES2972227T3 (es) 2024-06-11
US20160144035A1 (en) 2016-05-26
US20200368355A1 (en) 2020-11-26
US20160296621A1 (en) 2016-10-13
JP2022141895A (ja) 2022-09-29
HRP20240056T1 (hr) 2024-03-29
US9597397B2 (en) 2017-03-21
US9572887B2 (en) 2017-02-21
CN104302291A (zh) 2015-01-21
US20160296622A1 (en) 2016-10-13
DK2827862T3 (da) 2024-02-12
US9034908B2 (en) 2015-05-19
US20210106686A1 (en) 2021-04-15
JP2024045290A (ja) 2024-04-02
EP2827862A1 (en) 2015-01-28
JP2022130629A (ja) 2022-09-06
SI2827862T1 (sl) 2024-03-29
PT2827862T (pt) 2024-03-06
US20230285563A1 (en) 2023-09-14
US9597398B2 (en) 2017-03-21
CA2867295A1 (en) 2013-09-26
US20160000759A1 (en) 2016-01-07
US9144568B1 (en) 2015-09-29
WO2013142358A1 (en) 2013-09-26
US20130253025A1 (en) 2013-09-26
JP2015510939A (ja) 2015-04-13
EP2827862B1 (en) 2023-12-27
US20220265829A1 (en) 2022-08-25
US20140094496A1 (en) 2014-04-03
JP2018070624A (ja) 2018-05-10
US10052385B2 (en) 2018-08-21
US20200282057A1 (en) 2020-09-10
PL2827862T3 (pl) 2024-05-06
JP6250628B2 (ja) 2017-12-20
US20140275196A1 (en) 2014-09-18
HUE064884T2 (hu) 2024-04-28
CA2867295C (en) 2020-08-11
JP2021178846A (ja) 2021-11-18
US20220323584A1 (en) 2022-10-13
EP2827862A4 (en) 2015-11-18
US20150250766A1 (en) 2015-09-10
US20180000938A1 (en) 2018-01-04
US9597399B2 (en) 2017-03-21
US9572888B2 (en) 2017-02-21
EP4360621A3 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
FI2827862T3 (fi) Bendamustiinin formulaatioita
FI3533447T3 (fi) Menetelmä bendamustiiniin reagoivien tilojen hoitamiseksi alennettuja annostelutilavuuksia tarvitsevilla potilailla
GT201300235A (es) Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas
JP2015510939A5 (enExample)
MX379425B (es) 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, análogos y sales del mismo y su uso en terapia.
MX360638B (es) Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos.
NZ732507A (en) Improved compositions for treating muscular dystrophy
FI3377534T3 (fi) Keuhkosyövän hoito käyttäen anti-pd-1-vasta-aineen ja anti-ctla-4-vasta-aineen yhdistelmää
EA201591932A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
HRP20180007T1 (hr) Formulacija koja sadrži gemcitabin-predlijek
CU23814A3 (es) Emulsión intravenosa de butilftalida y aplicación de la misma
JP2014527061A5 (enExample)
SI2945620T1 (en) Nitroxyl donors with improved therapeutic index
WO2013156488A3 (en) Optimised subcutaneous therapeutic agents
DOP2012000143A (es) Procedimiento para la preparacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificacion para el uso como principio activo farmaceutico
AR082691A1 (es) Terapia de combinacion, producto farmaceutico, kit y uso
EP4606430A3 (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration
MX2022001966A (es) 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9- hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
ECSP21031139A (es) Formulaciones de anticuerpos anti-fgfr2
WO2011156481A3 (en) Formulations including amiodarone and salts thereof and methods of their manufacture and use
NZ610441A (en) Methods for enhancing oxygenation of jeopardized tissue
WO2012127277A3 (en) Bendamustine anionic-catioinic cyclopolysaccharide compositions
WO2014062228A8 (en) An improved nanovector based drug delivery system for overcoming drug resistance
ES2656913T3 (es) Endrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo